faculty

CMHCC Co-Chairs

Rachel Goodwin, MSc, MD, FRCPC

Assistant Professor of Medicine,
Faculty of Medicine, University of Ottawa
Ottawa, ON

Dr. Rachel Goodwin graduated from Mount Saint Vincent University with a Bachelor of Science and from the University of Guelph with a Masters of Nutritional Science.  She completed medical school and her internal medicine and medical oncology residency at the University of Ottawa.  Dr. Goodwin went on to complete a two-year Investigational New Drug Development Fellowship at NCIC Clinical Trial Group at Queen’s University, with a focus on Phase I/Phase II cancer clinical trials.
She is an Assistant Professor in the Faculty of Medicine at the University of Ottawa.  Her clinical interests include gastrointestinal cancers, neuroendocrine cancers and new drug development.  Dr. Goodwin is an active member of the Canadian Cancer Trials Group where she is New Drug Development Liaison and co-chair for the Colon Disease Site Group.

Jennifer Knox, MSc, MD, FRCPC

Professor, Dept. of Medicine,
University of Toronto

Dr. Jennifer Knox is a Professor of Medicine at the University of Toronto, working as a staff Medical Oncologist and Researcher since 2001. Dr. Knox is currently the head of Solid Tumour Medical Oncology Group at the Princess Margaret Cancer Centre in Toronto and Co-Director of the McCain Centre for Pancreatic Cancer.   She received her medical degree from the University of Toronto in 1995 and completed her Internal Medicine and Medical Oncology specialty training at the University of Toronto.  Her research interests include multidisciplinary therapeutic and translational trials in pancreas and hepatobiliary cancers.  She has been the study chair of a number of clinical trials conducted with The Canadian Clinical Trials Group (CCTG), The US National Cancer Institute and with Pharma, now with over 250 research publications. Her significant career awards include the Wilfred G. Lewitt Chair in Pancreatic Cancer Research in 2017, and was recognized in 2019 with the U of T divisional Research Achievement award.    Dr. Knox’s leadership is felt internationally as she chairs cancer research groups with CCTG, the Cholangiocarcinoma Society and NCI- US intergroup Task Force for Trials in Hepatobiliary Cancers. As a speaker she is sought after to promote clinical research programs and better patient care strategies.

Brandon Meyers, MSc, MD, FRCPC

Associate Professor, Oncology
McMaster University
Hamilton, ON

Dr. Meyers completed medical school at the University of Ottawa.  He then completed at McMaster University post-graduate training in Internal Medicine, and Medical Oncology followed by a fellowship in Gastrointestinal Malignancies. He is an Associate Professor and staff Medical Oncologist at the Juravinski Cancer Centre in Hamilton, Ontario. His gastrointestinal clinical practice primarily focuses on hepatocellular carcinoma.  He recently helped develop the Cancer Care Ontario guidelines on the management of advanced hepatocellular carcinoma, and is involved in phase I-III trials examining novel agents for liver cancer.  He also collaborates with basic scientists working with animal models of liver cancer.  He is a member of the Planning Committee of the Canadian Multidisciplinary HCC Conference.

Vincent Tam, MD, FRCPC

Associate Clinical Professor,
University of Calgary
Calgary, AB

Dr. Vincent Tam is Associate Clinical Professor at the University of Calgary and a staff medical oncologist at the Tom Baker Cancer Centre. He specializes in the treatment of gastrointestinal malignancies and particularly hepatobiliary cancer. His research interests include clinical trials in hepatobiliary cancer and real world outcomes of HCC patients treated with various systemic therapies.

Planning Committee 

Kelly Burak, MD, MSc (Epid), FRCPC

Professor of Medicine,
Associate Dean, Continuing Medical Education & Professional Development
Co-Lead, Physician Learning Program
Unniversity of Calgary
Calgary, AB

Dr. Kelly Burak received his BSc (Biology), MD and Internal Medicine training at the University of Saskatchewan before completing training in gastroenterology in Calgary. He completed a CASL/MRC Research Fellowship in Hepatology at the University of Calgary followed by a Clinical
Fellowship in Hepatology and Liver Transplantation at the Mayo Clinic in Rochester, Minnesota. In 2005, Dr. Burak was awarded his MSc in Epidemiology from the University of Calgary, and in 2012 he obtained a Graduate Certificate in Clinical Education from Flinders University in Adelaide, Australia.

Dr. Burak is currently a Professor of Medicine at the University of Calgary and is cross-appointed to the Department of Oncology. He served as the Director of the Southern Alberta Liver Transplant Clinic for 18 years and the Director of the Calgary Liver Unit for 8 years. Dr. Burak has more than 100 peer-reviewed publications, which include clinical practice guidelines on the management of viral hepatitis and liver cancer.

Kelly has a passion for medical education and has won a number of teaching awards, both locally and nationally, including the Canadian Association of Gastroenterology Young Educator Award and the Canadian Association for the Study of the Liver Excellence in Education Award. In 2017, Dr. Burak became the Associate Dean of Continuing Medical Education & Professional Development at the University of Calgary and the Co-Lead of the Physician Learning Program.

Laura Dawson MD, FRCPC, FASTRO

Professor, University of Toronto
Radiation Oncologist, Princess Margaret Cancer Centre
Toronto, ON

Dr. Laura Dawson is a Professor in the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is the multi-disciplinary hepatobiliary cancer and pancreatic cancer site lead for the Princess Margaret Cancer Committee. She is an internationally recognized leader in hepatocellular carcinoma and in oligo-metastases stereotactic body radiation therapy (SBRT). She is the principal investigator of two randomized phase III clinical trials investigating the use of radiation therapy in hepatocellular carcinoma (RTOG1112 and CCTG HE1).

David Liu, MD, FRCPC, FSIR 

Associate Professor, Department of Radiology, Faculty of Medicine, University of British Columbia
Associate Professor, School of Biomedical Engineering, Faculty of Applied Sciences, University of British Columbia
Voluntary Professor, Department of Interventional Radiology, Miller School of Medicine, University of Miami
Vancouver, BC

Dr David M Liu MD is a board certified in both Canada and the US, practicing at the Vancouver General Hospital, University of British Columbia Hospital and the BC Cancer Agency with a cross appointment in the Department of Surgery. Dr Liu received his medical degree from University of Toronto, completed his radiology residency at University of British Columbia, Interventional Radiology fellowship at Northwestern Memorial Hospital, and has practiced in both the US and Canada.

In addition to benchside and clinical research in the fields of novel embolic platforms, ablative technologies and cancer related thromboembolic disease, Dr Liu maintains an interventional oncology practice incorporating all aspects of embolization, ablation, venous access, and palliative therapy in all organ systems. He is the co-founder and co-chair of the international liver cancer symposium, SHOW, and has been credited with 7 book chapters, over 70 publications, and over 100 invited lectures around the world. Dr Liu an active member of the interventional radiology community as recognized through his induction as a Fellow of the Society of Interventional Radiology, and has been awarded the CIRA award from the Canadian Association of Interventional Radiology (CAIR) in recognition of his extraordinary contribution to the practice of IR in Canada and worldwide.

Dr Liu holds numerous academic appointments including:

Associate Professor, Faculty of Medicine, Department of Radiology, University of British Columbia, Vancouver, Canada

Associate Professor, Faculty of Applied Sciences, School of Biomedical Engineering, University of British Columbia, Vancouver, Canada

Voluntary Professor, Miller School of Medicine, Department of Interventional Radiology, Miami, USA

Gonzalo Sapisochin MD, PhD, MSc

Associate Professor of Surgery
Abdominal Transplant & HPB Surgery
University Health Network, University of Toronto
Toronto, ON

Dr. Sapisochin is an Associate Professor at the University of Toronto and staff surgeon at the University Health Network. He specializes in the surgical management of hepatobiliary malignancies, in particular hepatocellular carcinoma and cholangiocarcinoma. His research interest includes the interface between organ transplantation and cancer, clinical outcomes of patients with hepatocellular carcinoma and clinical trials in this domain.

Faculty

Robert Beecroft, MD, FRCPC

Staff Vascular and Interventional Radiologist
University Health Network – Mount Sinai Hospital
Toronto, ON

Dr Rob Beecroft is a staff Vascular and Interventional Radiologist at University Health Network – Mount Sinai Hospital in Toronto with specialized interest in locoregional therapies for HCC and hepatic malignancies.

Giammauro Berardi, MD, PhD

Surgeon
Department of General and Hepatobiliary Surgery
Liver Transplantation Service
San Camillo Forlanini Hospital
Rome, IT

 Dr. Giammauro Berardi earned his medical degree in Rome, Italy where he also took his general surgery residency. After graduating, he moved to Gent in Belgium where he took his PhD in surgery focusing on living donor liver surgery and the application of minimally invasive technique in HPB. He then moved to Japan for a fellowship in advanced HPB surgery under the proctorship of Prof. Go Wakabayashi. He finally spent one extra year of clinical fellowship in the United States where he focused on Surgical Oncology at the Memorial Sloan Kettering Cancer Center in New York. He has more than 100 publications in high impact international journals and his research focuses on liver and pancreatic cancers, liver cirrhosis and minimally invasive techniques in liver surgery. He is an active board member of the International Laparoscopic Liver Society (ILLS). He now works at the San Camillo Forlanini hospital in Rome where he specializes in HPB malignancies and Liver Transplantation.

Richard S. Finn, MD

Professor
Department of Medicine
Division of Hematology/ Oncology
UCLA David Geffen School of Medicine
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
University of California
Los Angeles

Dr Finn is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research.  His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer.  Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others.  An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine.  He has brought several practice changing advanced to cancer medicine. He played a lead role in  the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration and more recently the combination of  atezolizumab and bevacizumab for the treatment of advanced liver cancer.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He is a past president of the International Liver Cancer Association (ILCA).  He is on the editorial board of Clinical Cancer Research.

Ali Hosni, MD

Assistant Professor, Dept. of Radiation Oncology
University of Toronto
Staff Radiation Oncologist (Clinician Investigator), Dept. of Radiation Oncology Princess Margaret Cancer Centre, University of Toronto
Toronto, ON

Dr. Hosni’s research focus relates to his Ph.D., and is aligned with his training and clinical expertise in head and neck, and gastrointestinal malignancies. Dr. Hosni has global interest in clinical and experimental radiobiology with specific focus on the radiobiological principles that derive the tumor response and treatment-related toxicity. Dr. Hosni’s  research is centered on developing optimal radiation therapeutic approach and uncovering novel biomarkers of radiation response and toxicities.

Howard Lim, MD, PhD, FRCPC

Clinical Associate Professor
Faculty of Medicine, UBC
Medical Oncologist
BC Cancer- Vancouver Centre
Vancouver, BC

Howard Lim is a Medical Oncologist at B.C Cancer – Vancouver Centre and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia.  He specializes in gastrointestinal malignancies and is actively involved in clinical trials, ethics and genomic based research.

Ravi Ramjeesingh, MD, PhD, FRCPC

Associate Professor
Division of Medical Oncology
Dalhousie University
Halifax, NS

DrRamjeesingh joined the Division of Medical Oncology at Dalhousie University in May 2015 as a staff physician and Associate Professor. He completed his Ph.D in cancer research in 2004, and his doctor of medicine in 2008 at the University of Toronto. He then subsequently completed his Internal Medicine and Medical Oncology residencies at Queen’s University before completed a clinical trials methodology fellowship at the Canadian Clinical Trials Group (CCTG) in Kingston, Ontario where he also received a CAMO-CIHR fellowship. His main clinical expertise is in the areas of hepatobiliary cancers including pancreatic and hepatocellular carcinoma, and breast cancer. He is currently the chair of the HPB Disease site group in Nova Scotia and is the Director of Research in the division of medical oncology. His research activities and interests are in the fields of Health service delivery, and translational research in Oncology. He has been awarded the Department of Medicine Research Excellent award in 2017 and the DOM Excellence in Medical Education award in 2018.